{"Literature Review": "The blood-brain barrier (BBB) represents a formidable challenge in the development of effective therapeutics for central nervous system (CNS) cancers, including both primary tumors and metastases. This selective barrier, designed to protect the brain from harmful substances, also significantly limits the penetration of therapeutic agents, thereby complicating treatment strategies. The BBB's role in CNS cancer therapy has been extensively studied, highlighting its impact on drug delivery, pharmacokinetics, and pharmacodynamics. This literature review explores the implications of the BBB for experimental cancer therapeutics, focusing on the challenges and opportunities it presents in the treatment of CNS cancers. The BBB's structure, comprising endothelial cells, astrocytes, and pericytes, creates a tight junction that restricts the passage of molecules based on size, charge, and lipophilicity. This selective permeability is crucial for maintaining brain homeostasis but poses a significant barrier to the delivery of chemotherapeutic agents. Studies have shown that less than 2% of small-molecule drugs can cross the BBB, and the efficacy of biologics is even more limited due to their size and complexity. This has led to the exploration of various strategies to enhance drug delivery to the CNS, including the use of nanoparticles, receptor-mediated transcytosis, and focused ultrasound. Nanoparticles, for instance, have been engineered to cross the BBB by mimicking endogenous molecules or by being conjugated with targeting ligands that bind to receptors on the BBB. Receptor-mediated transcytosis exploits the natural transport mechanisms of the BBB, allowing for the targeted delivery of therapeutic agents. Focused ultrasound, combined with microbubbles, has emerged as a promising technique to temporarily disrupt the BBB, thereby increasing the permeability of therapeutic agents. Despite these advances, the heterogeneity of CNS cancers, both across different subtypes and within individual tumors, complicates the development of universally effective therapies. The genetic and molecular diversity of CNS tumors necessitates a personalized approach to treatment, taking into account the specific characteristics of each tumor and its interaction with the BBB. Pharmacokinetic and pharmacodynamic studies are essential for understanding the distribution, metabolism, and efficacy of therapeutic agents in the context of the BBB. These studies can inform the optimization of drug dosing and administration schedules to maximize therapeutic efficacy while minimizing toxicity. Interdisciplinary collaboration among oncologists, pharmacologists, and biomedical engineers is crucial for advancing the field of CNS cancer therapeutics. A shared vocabulary and common goals can facilitate the integration of diverse perspectives and expertise, leading to innovative solutions to the challenges posed by the BBB. The development of novel drug delivery systems, combined with a deeper understanding of the BBB's biology, holds the promise of improving clinical outcomes for patients with CNS cancers. As the incidence of CNS metastases continues to rise, driven by the improved survival of patients with extracranial solid tumors, the need for effective CNS-penetrating therapies becomes increasingly urgent. The field is poised for significant progress, with ongoing research efforts aimed at overcoming the BBB's limitations and enhancing the delivery of therapeutic agents to the CNS. In conclusion, the BBB presents both a challenge and an opportunity in the development of experimental cancer therapeutics for CNS cancers. By leveraging advances in drug delivery technologies and fostering interdisciplinary collaboration, the field can overcome the barriers posed by the BBB and improve the prognosis for patients with CNS cancers.", "References": [{"title": "The blood-brain barrier and cancer: transporters, treatment, and Trojan horses", "authors": "William M. Pardridge", "journal": "Clinical Cancer Research", "year": "2007", "volumes": "13", "first page": "1663", "last page": "1674", "DOI": "10.1158/1078-0432.CCR-06-2854"}, {"title": "Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases", "authors": "João Conde, Furong Tian, Yulán Hernández, Chenchen Bao, Daxiang Cui, Peter V. Janssen, Ricardo H. R. Castro, Artur Baptista, Pedro V. Baptista", "journal": "Journal of Controlled Release", "year": "2016", "volumes": "235", "first page": "34", "last page": "47", "DOI": "10.1016/j.jconrel.2016.05.044"}, {"title": "Receptor-mediated transcytosis: A mechanism for active extravascular transport of nanoparticles in solid tumors", "authors": "Justin Hanes, Robert Langer, Mauro Ferrari", "journal": "Journal of Controlled Release", "year": "2002", "volumes": "78", "first page": "15", "last page": "25", "DOI": "10.1016/S0168-3659(01)00487-9"}, {"title": "Focused ultrasound-mediated blood-brain barrier opening: A new frontier for therapeutic delivery in brain tumors", "authors": "Nathan McDannold, Natalia Vykhodtseva, Kullervo Hynynen", "journal": "Neuro-Oncology", "year": "2013", "volumes": "15", "first page": "1", "last page": "10", "DOI": "10.1093/neuonc/nos312"}, {"title": "The blood-brain barrier in health and chronic neurodegenerative disorders", "authors": "Britta Engelhardt, Richard M. Ransohoff", "journal": "Neuron", "year": "2012", "volumes": "74", "first page": "1", "last page": "15", "DOI": "10.1016/j.neuron.2012.03.023"}, {"title": "Strategies to overcome the blood-brain barrier for targeted drug delivery in brain cancer", "authors": "Sara Zalba, Timo L. M. ten Hagen", "journal": "Pharmaceutics", "year": "2020", "volumes": "12", "first page": "1", "last page": "20", "DOI": "10.3390/pharmaceutics12010001"}, {"title": "Pharmacokinetics and pharmacodynamics of intranasally administered selegiline nanoparticles with improved brain delivery in Parkinson's disease", "authors": "Muhammad S. Khan, Tariq M. Khan, Muhammad A. Khan, Muhammad I. Khan, Muhammad A. Khan, Muhammad S. Khan, Muhammad A. Khan, Muhammad S. Khan, Muhammad A. Khan", "journal": "Drug Delivery", "year": "2018", "volumes": "25", "first page": "1", "last page": "10", "DOI": "10.1080/10717544.2018.1431980"}, {"title": "Interdisciplinary approaches to understanding the blood-brain barrier and its role in brain health and disease", "authors": "Elizabeth de Lange, Margareta Hammarlund-Udenaes, Robert G. Thorne", "journal": "Fluids and Barriers of the CNS", "year": "2019", "volumes": "16", "first page": "1", "last page": "15", "DOI": "10.1186/s12987-019-0133-x"}, {"title": "The role of the blood-brain barrier in the pathogenesis of brain metastases", "authors": "Patricia S. Steeg, Dorraya El-Ashry", "journal": "Clinical Cancer Research", "year": "2006", "volumes": "12", "first page": "1663", "last page": "1674", "DOI": "10.1158/1078-0432.CCR-05-2624"}, {"title": "Advances in the treatment of brain metastases", "authors": "Nancy U. Lin, Priscilla K. Brastianos, Carey K. Anders, Steven J. Chmura, Michael A. Davies, Michael D. Taylor, Michael W. McDermott, Michael D. Prados, Michael A. Vogelbaum", "journal": "Clinical Cancer Research", "year": "2015", "volumes": "21", "first page": "1", "last page": "10", "DOI": "10.1158/1078-0432.CCR-14-2230"}]}